CN107106530A - 治疗多发性硬化的方法 - Google Patents

治疗多发性硬化的方法 Download PDF

Info

Publication number
CN107106530A
CN107106530A CN201580072773.3A CN201580072773A CN107106530A CN 107106530 A CN107106530 A CN 107106530A CN 201580072773 A CN201580072773 A CN 201580072773A CN 107106530 A CN107106530 A CN 107106530A
Authority
CN
China
Prior art keywords
fumarate
patient
pharmaceutical composition
foregoing
monoalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580072773.3A
Other languages
English (en)
Chinese (zh)
Inventor
马克·诺瓦斯
张睿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107106530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Priority to CN202211204459.4A priority Critical patent/CN115501218A/zh
Priority to CN202110624861.7A priority patent/CN113368093A/zh
Priority to CN202110623846.0A priority patent/CN113368091A/zh
Priority to CN202211204481.9A priority patent/CN115531366A/zh
Priority to CN202110623848.XA priority patent/CN113368092A/zh
Publication of CN107106530A publication Critical patent/CN107106530A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Business, Economics & Management (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Theoretical Computer Science (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Educational Administration (AREA)
CN201580072773.3A 2014-11-17 2015-11-16 治疗多发性硬化的方法 Pending CN107106530A (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202211204459.4A CN115501218A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110624861.7A CN113368093A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623846.0A CN113368091A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202211204481.9A CN115531366A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623848.XA CN113368092A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462080783P 2014-11-17 2014-11-17
US62/080,783 2014-11-17
US201562140255P 2015-03-30 2015-03-30
US62/140,255 2015-03-30
US201562232963P 2015-09-25 2015-09-25
US62/232,963 2015-09-25
PCT/US2015/060850 WO2016081355A1 (en) 2014-11-17 2015-11-16 Methods of treating multiple sclerosis

Related Child Applications (5)

Application Number Title Priority Date Filing Date
CN202211204481.9A Division CN115531366A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202211204459.4A Division CN115501218A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623848.XA Division CN113368092A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110624861.7A Division CN113368093A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623846.0A Division CN113368091A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法

Publications (1)

Publication Number Publication Date
CN107106530A true CN107106530A (zh) 2017-08-29

Family

ID=54771192

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201580072773.3A Pending CN107106530A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202211204459.4A Pending CN115501218A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202211204481.9A Pending CN115531366A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110624861.7A Pending CN113368093A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623846.0A Pending CN113368091A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623848.XA Pending CN113368092A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN202211204459.4A Pending CN115501218A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202211204481.9A Pending CN115531366A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110624861.7A Pending CN113368093A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623846.0A Pending CN113368091A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法
CN202110623848.XA Pending CN113368092A (zh) 2014-11-17 2015-11-16 治疗多发性硬化的方法

Country Status (13)

Country Link
US (9) US20170354630A1 (https=)
EP (3) EP3220907A1 (https=)
JP (5) JP6786486B2 (https=)
KR (3) KR20240035912A (https=)
CN (6) CN107106530A (https=)
AU (4) AU2015350213A1 (https=)
CA (1) CA2967619C (https=)
EA (1) EA038370B1 (https=)
IL (2) IL269885B (https=)
MA (2) MA40985A (https=)
MX (1) MX2017006473A (https=)
WO (1) WO2016081355A1 (https=)
ZA (1) ZA201703207B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111440771A (zh) * 2020-03-17 2020-07-24 中山大学附属第三医院 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10391160B2 (en) 2014-03-14 2019-08-27 Biogen Ma Inc. Dimethyl fumarate and vaccination regimens
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
HUE055210T2 (hu) 2015-02-08 2021-11-29 Alkermes Pharma Ireland Ltd Monometilfumarát prodrug készítmények
US10868332B2 (en) 2016-04-01 2020-12-15 NOHMs Technologies, Inc. Modified ionic liquids containing phosphorus
JP7296893B2 (ja) 2017-07-17 2023-06-23 ノームズ テクノロジーズ インコーポレイテッド リン含有電解質
CA3175830A1 (en) * 2019-04-17 2020-10-22 Sundeep Dugar Prodrugs of monomethyl fumarate
AU2020283238B2 (en) * 2019-05-31 2022-07-07 Curacle Co., Ltd. Enteric tablet containing dimethyl fumarate
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
TW202131914A (zh) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案
EP4146190A2 (en) 2020-05-06 2023-03-15 Imcyse SA Combination treatment for fumarate-related diseases
KR102713565B1 (ko) * 2020-11-27 2024-10-07 주식회사 뷰노 의료 영상 기반의 뇌백질 병변 탐지 방법
WO2022203432A1 (ko) * 2021-03-25 2022-09-29 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
KR102566549B1 (ko) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
US20250181224A1 (en) * 2023-12-01 2025-06-05 Lemon Inc. Implementing dialog-based image editing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732062A (zh) * 2011-05-26 2014-04-16 比奥根艾迪克Ma公司 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
SI2139467T1 (sl) * 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
RS56977B1 (sr) 2010-01-11 2018-05-31 Biogen Ma Inc Test za antitela protiv jc virusa
PL3575792T3 (pl) 2011-05-31 2023-03-27 Biogen Ma Inc. Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)
NZ627980A (en) 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
WO2014031901A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
US20150157590A9 (en) 2012-11-05 2015-06-11 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
US9868690B2 (en) 2012-12-21 2018-01-16 Ratiopharm Gmbh Prodrugs of monomethyl fumarate (MMF)
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20140322251A1 (en) 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
JP2016527276A (ja) 2013-08-01 2016-09-08 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10391160B2 (en) 2014-03-14 2019-08-27 Biogen Ma Inc. Dimethyl fumarate and vaccination regimens
WO2016057133A1 (en) 2014-10-08 2016-04-14 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
WO2017040272A1 (en) 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
WO2017151184A1 (en) 2016-02-29 2017-09-08 Banner Life Sciences Llc Fumarate ester dosage forms
US10523918B2 (en) 2017-03-24 2019-12-31 Samsung Electronics Co., Ltd. System and method for depth map

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732062A (zh) * 2011-05-26 2014-04-16 比奥根艾迪克Ma公司 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OOSTEN等: "PML in a patient treated with dimethyl fumarate from a compounding pharmacy", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
周官恩等: "多发性硬化口服药物研究新进展", 《中国现代神经疾病杂志》 *
郭丽萍等: "多发性硬化的治疗进展", 《中国临床神经科学》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111440771A (zh) * 2020-03-17 2020-07-24 中山大学附属第三医院 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系

Also Published As

Publication number Publication date
US20200345679A1 (en) 2020-11-05
CA2967619A1 (en) 2016-05-26
EA201791101A1 (ru) 2017-12-29
NZ731528A (en) 2021-11-26
AU2020239734A1 (en) 2020-10-15
US11007166B2 (en) 2021-05-18
IL269885B (en) 2022-06-01
WO2016081355A1 (en) 2016-05-26
IL252296A0 (en) 2017-07-31
US20170354630A1 (en) 2017-12-14
US20210023040A1 (en) 2021-01-28
CN115501218A (zh) 2022-12-23
US20170368013A1 (en) 2017-12-28
AU2015350213A1 (en) 2017-05-25
US20180000770A1 (en) 2018-01-04
IL252296B (en) 2022-06-01
US20190125710A1 (en) 2019-05-02
US11129806B2 (en) 2021-09-28
EA038370B1 (ru) 2021-08-17
JP2022168243A (ja) 2022-11-04
US10959972B2 (en) 2021-03-30
JP2017537089A (ja) 2017-12-14
JP6830941B2 (ja) 2021-02-17
CA2967619C (en) 2022-06-28
MX2017006473A (es) 2018-01-30
KR102299842B1 (ko) 2021-09-09
US20210315854A1 (en) 2021-10-14
US11246850B2 (en) 2022-02-15
US20260007627A1 (en) 2026-01-08
ZA201703207B (en) 2021-08-25
AU2024203437A1 (en) 2024-06-13
EP3804711A1 (en) 2021-04-14
JP2025109834A (ja) 2025-07-25
KR20210111362A (ko) 2021-09-10
EP4215191A1 (en) 2023-07-26
KR20170084270A (ko) 2017-07-19
MA53882A (fr) 2021-12-08
EP3220907A1 (en) 2017-09-27
AU2021269298A1 (en) 2021-12-09
CN113368093A (zh) 2021-09-10
JP2020196760A (ja) 2020-12-10
JP6786486B2 (ja) 2020-11-18
US11007167B2 (en) 2021-05-18
MA40985A (fr) 2017-09-26
CN113368091A (zh) 2021-09-10
US20190008817A1 (en) 2019-01-10
CN113368092A (zh) 2021-09-10
CN115531366A (zh) 2022-12-30
JP2019023248A (ja) 2019-02-14
KR20240035912A (ko) 2024-03-18

Similar Documents

Publication Publication Date Title
US11246850B2 (en) Methods of treating multiple sclerosis
CA2641160A1 (en) Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
HK40097430A (en) Composition comprising a fumarate for use in a method of treating multiple sclerosis
HK40047494A (en) Methods of treating multiple sclerosis
NZ731528B2 (en) Methods of treating multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170829